Roche agreed to pay Nurix Therapeutics $700 million upfront to co-develop and co-commercialize its BTK degrader bexobrutideg. The arrangement, valued at up to $2.3 billion in milestones, is designed to pit an oral protein-degradation approach against established BTK inhibitor competition in B-cell malignancies. The companies said they will split U.S. profits equally while Roche holds responsibility outside the U.S., with royalties in the low- to high-teens. Roche will pay 60% of development costs, and the deal includes a planned phase 3 confirmatory trial comparing bexobrutideg with Lilly’s Jaypirca in patients with CLL/SLL previously treated with a covalent BTK inhibitor. Nurix reported early progression-free survival signals in a phase 1a study, and Roche and Nurix positioned BTK degradation as a differentiator versus inhibitors that block enzymatic activity. Roche and Nurix said the collaboration supports broader development plans beyond BTK-targeted oncology.